Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Travere Therapeutics's enterprise value was $4.61B on Nov 11, 2026, against $2.92B a year earlier. Over the last 5 years it ranged from $109.97M to $5.95B, with a median of $1.14B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.61B | +45.4% |
| 2025 | Dec 31, 2025 | $3.17B | +187.6% |
| 2024 | Dec 31, 2024 | $1.10B | +246.1% |
| 2023 | Dec 29, 2023 | $318.38M | -64.7% |
| 2022 | Dec 30, 2022 | $901.00M | -37.5% |
| 2021 | Dec 31, 2021 | $1.44B | +45.4% |
| 2020 | Dec 31, 2020 | $991.37M | +215.8% |
| 2019 | Dec 31, 2019 | $313.91M | -48.0% |
| 2018 | Dec 31, 2018 | $603.35M | -17.2% |
| 2017 | Dec 29, 2017 | $728.65M | +5.6% |
| 2016 | Dec 30, 2016 | $689.84M | +24.5% |
| 2015 | Dec 31, 2015 | $554.00M | +64.7% |
| 2014 | Dec 31, 2014 | $336.46M | +192.0% |
| 2013 | Dec 31, 2013 | $115.22M | +32493.6% |
| 2012 | Dec 31, 2012 | $353.52K | – |
See a number that looks wrong?